Let’s Discuss Postpartum Depression: Screening, Diagnosis, and Management

Let’s Discuss Postpartum Depression: Screening, Diagnosis, and Management

CME/CE Broadcast Replay

ReachMD Healthcare Image

Experts shine a light on how postpartum depression and its treatment impact the health and quality of life of new mothers and their babies.

Available credits: 0.75

Time to complete: 45 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This animated Women’s Health 2022 lecture features a discussion between Drs. Jennifer Payne and Anita Clayton who clearly highlight the importance of screening for perinatal and postpartum depression (PPD). Our experts delve into the critical importance of proactively diagnosing and treating women during the various stages of pregnancy and review the latest therapies that specifically target PPD. Find out how these therapies compare to traditional antidepressants and how PPD treatment can improve the health and quality of life for patients and their families. What changes can you implement into your clinical practice to improve maternal and infant health?

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Anita H. Clayton, MD
    Professor & Chair
    Department of Psychiatry and Neurobehavioral Sciences
    University of Virginia
    Charlottesville, VA

    Contracted Research: Daré Bioscience, Janssen, Otsuka, Praxis Precision Medicines, Relmada Therapeutics, Inc., Sage Therapeutics, Takeda
    Consulting Fees: Fabre-Kramer, Janssen Research & Development, LLC., Mind Cure Health, Ovoca Bio PLC, PureTech Health, Reunion Neuroscience (formerly Field Trip Health), S1 Biopharma, Sage Therapeutics, Takeda/Lundbeck, Vella Bioscience, Inc, WCG MedAvante-ProPhase
    Ownership Interest: Euthymics, Mediflix LLC, S1 Biopharma
    Royalty: Ballantine Books/Random House; Changes in Sexual Functioning Questionnaire; Guilford Publications

    Jennifer L. Payne, MD
    Professor and Vice Chair of Research
    Department of Psychiatry and Neurobehavioral Sciences
    University of Virginia
    Charlottesville, VA

    Consulting Fees: Brii Bio CNS, Karuna, PureTech, Sage Therapeutics

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss optimal approaches for earlier identification of postpartum depression symptoms in pregnant women and new mothers
    • Understand the pharmacologic and nonpharmacologic options for treating mild, moderate, and severe postpartum depression
    • Compare the MOAs of standard antidepressants and neuroactive steroids for the treatment of postpartum depression 
    • Discuss the efficacy and safety findings from clinical trials of approved and emerging therapies for postpartum depression
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians, gynecologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .75 AAPA Category 1 CME credits. Approval is valid until December 12, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Biogen, Inc. and Sage Therapeutics, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free